Recursion director Borgeson plans $155K share sale

The shares are identified as Founders Shares acquired from the issuer for compensation on September 19, 2017.

Available on EDGAR 11/03/2026 - 11:24 AM EST Accepted by SEC EDGAR 11/03/2026 - 11:24 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. (RXRX) director Blake C. Borgeson reported a planned sale of 40,000 Class A shares, with an aggregate market value of $155,200, through Fidelity Brokerage Services LLC on approximately November 3, 2026; NASDAQ is listed as the exchange. The notice also lists three Class A sales during the past three months.

Key Figures

Planned sale: 40,000 Class A shares Aggregate market value: $155,200 Shares sold: 30,000 shares +5 more

8 metrics

Planned sale 40,000 Class A shares Approximate sale date November 3, 2026

Aggregate market value $155,200 Planned Class A sale

Shares sold 30,000 shares August 4, 2026

Gross proceeds $97,500 Class A sale on August 4, 2026

Shares sold 30,000 shares September 1, 2026

Gross proceeds $100,200 Class A sale on September 1, 2026

Shares sold 50,000 shares October 6, 2026

Gross proceeds $242,000 Class A sale on October 6, 2026

Key Terms

Rule 144, Founders Shares, attorney-in-fact

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Founders Shares financial

"Founders Shares"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

attorney-in-fact regulatory

"as attorney-in-fact for Blake C. Borgeson"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RXRX shares did Blake C. Borgeson plan to sell?

Blake C. Borgeson, a director of Recursion Pharmaceuticals, Inc. (RXRX), reported a planned sale of 40,000 Class A shares with an aggregate market value of $155,200. Fidelity Brokerage Services LLC is named as broker, the approximate sale date is November 3, 2026, and NASDAQ is listed as the exchange.

What RXRX shares did Blake C. Borgeson sell in the past three months?

The notice lists sales of 30,000 shares for $97,500 on August 4, 2026, 30,000 shares for $100,200 on September 1, 2026, and 50,000 shares for $242,000 on October 6, 2026. Each is listed as a Class A sale.

How did Blake C. Borgeson acquire the RXRX shares listed for sale?

The 40,000 Class A shares are identified as Founders Shares acquired from the issuer for compensation on September 19, 2017.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001856094
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	RECURSION PHARMACEUTICALS, INC.
SEC File Number	001-40323
Address of Issuer	41S RIO GRANDE STREET SALT LAKE CITY UTAH 84101
Phone	(385) 269-0203
Name of Person for Whose Account the Securities are To Be Sold	Borgeson Blake
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	40000	155200.00	622759259	11/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	09/19/2017	Founders Shares	Issuer			40000	09/19/2017	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Blake C. Borgeson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	08/04/2026	30000	97500.00
Blake C. Borgeson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	09/01/2026	30000	100200.00
Blake C. Borgeson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	10/06/2026	50000	242000.00

144: Remarks and Signature

Remarks
Date of Notice	11/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/31/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Blake C. Borgeson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)